Drugs / Compound Realgar-Indigo Naturalis Formula
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04175587 | Dec 2019 → Aug 2021 | acute promyelocytic leukemia | Peking University People's Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Compound Realgar-Indigo Naturalis Formula | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04175587 ↗ |
| Route | Oral | “developed and designed an oral arsenic” NCT04175587 ↗ |